BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 7, 2026
Home » Topics » Coronavirus, BioWorld

Coronavirus, BioWorld
Coronavirus, BioWorld RSS Feed RSS

Akston starts small and likes it that way

Sep. 7, 2022
By Lee Landenberger
Akston Biosciences Corp. emerged from a successful small company that was sold to a pharma major. For Todd Zion, that’s a back-to-basics move that suits him just fine. Zion co-founded Smartcells Inc. in 2003 with technology developed at the Massachusetts Institute of Technology. The company went on to develop the once-daily injectable self-regulating insulin product, Smartinsulin, and sold it to Merck & Co. in what was at the time one of the largest preclinical pharmaceutical acquisitions ever.
Read More
Patient in hospital bed

Tubulin test: Veru coming through as COVID-19 queue debated

Sep. 7, 2022
By Randy Osborne
Wall Street trimmed shares of Veru Inc. (NASDAQ:VERU) by upwards of 20% in the wake of an editorial published Aug. 23 in The New England Journal of Medicine publication NEJM Evidence. The opinion piece, by two critical-care pulmonologists, added verve to the debate about the efficacy of drugs for people hospitalized with COVID-19.
Read More

Regulatory actions for Sept. 7, 2022

Sep. 7, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alvotech, Amylyx, Aston, Astrazeneca, Bausch + Lomb, Novaliq, Novavax, Tenaya.
Read More

In the clinic for Sept. 7, 2022

Sep. 7, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Alaunos, Bavarian Nordic, Boehringer Ingelheim, Clarity, Dizal, Dyne, Immutep, Innovent, Ironwood, Iveric, Jacobio, Laekna, Mannkind, Regeneron, Sanofi, Yingli, Zymeworks.
Read More
Green approved stamp

China clears two new COVID-19 boosters for emergency use

Sep. 6, 2022
By Doris Yu
China’s NMPA has granted emergency use authorization for two COVID-19 vaccines as boosters, Cansino Biologics Inc.’s inhaled vaccine Convidecia Air and Livzon Pharmaceutical Group Inc.’s recombinant protein vaccine. Convidecia Air is an aerosolized adenovirus type 5 vector-based vaccine. It is the first inhaled COVID-19 vaccine to be approved globally, according to Cansino.
Read More

Regulatory actions for Sept. 6, 2022

Sep. 6, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Azurity, Bayer, Boehringer, Immuneering, Intellia, Moderna, Novavax, Y-mabs.
Read More

Regulatory actions for Sept. 2, 2022

Sep. 2, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amneal, Aston, Biontech, Genentech, Immusoft, Moderna, Pfizer, Roche, Sanofi.
Read More

Other news to note for Sept. 2, 2022

Sep. 2, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bridge, Celsion, Ensysce, Helsinn, I-Cordis, Juniper, MC2, Quotient.
Read More

In the clinic for Sept. 2, 2022

Sep. 2, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Algo, Anaptysbio, Avacta, Axsome, Coya, Pliant, Reveragen, Santhera, Vaxart, Vyluma, Werewolf.
Read More

ACIP blesses bivalent vaccines for US market

Sep. 1, 2022
By Mari Serebrov
In the hope of preventing thousands of hospitalizations and deaths over the next few months, the U.S. CDC’s Advisory Committee on Immunization Practice (ACIP) voted 13-1 Sept. 1 to recommend the use of Moderna Inc.’s and Pfizer Inc.-Biontech SE’s updated vaccines that contain components of both the original SARS-CoV-2 virus and the omicron BA.4/5 subvariants as boosters.
Read More
Previous 1 2 … 48 49 50 51 52 53 54 55 56 … 357 358 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Regulatory actions for May 5, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing